CN101267816A - 使用氢醌安沙霉素的治疗方法 - Google Patents

使用氢醌安沙霉素的治疗方法 Download PDF

Info

Publication number
CN101267816A
CN101267816A CNA2006800335526A CN200680033552A CN101267816A CN 101267816 A CN101267816 A CN 101267816A CN A2006800335526 A CNA2006800335526 A CN A2006800335526A CN 200680033552 A CN200680033552 A CN 200680033552A CN 101267816 A CN101267816 A CN 101267816A
Authority
CN
China
Prior art keywords
alkyl
aralkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800335526A
Other languages
English (en)
Chinese (zh)
Inventor
J·亚当斯
J·布赖因
Y·高
A·T·乔治斯-埃文格利诺斯
D·格雷策尔
L·格雷尼尔
E·诺尔曼特
R·H·帕克
V·帕隆贝拉
J·R·波特
J·K·童
J·L·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Discovery Inc
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of CN101267816A publication Critical patent/CN101267816A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CNA2006800335526A 2005-07-13 2006-07-13 使用氢醌安沙霉素的治疗方法 Pending CN101267816A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/180,314 2005-07-13
US11/180,314 US20060019941A1 (en) 2003-12-23 2005-07-13 Analogs of benzoquinone-containing ansamycins and methods of use thereof

Publications (1)

Publication Number Publication Date
CN101267816A true CN101267816A (zh) 2008-09-17

Family

ID=37637939

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800335526A Pending CN101267816A (zh) 2005-07-13 2006-07-13 使用氢醌安沙霉素的治疗方法

Country Status (16)

Country Link
US (1) US20060019941A1 (https=)
EP (1) EP1904057B1 (https=)
JP (1) JP2009501234A (https=)
KR (1) KR20080030093A (https=)
CN (1) CN101267816A (https=)
AT (1) ATE451919T1 (https=)
AU (1) AU2006268196A1 (https=)
BR (1) BRPI0612870A2 (https=)
CA (1) CA2612506A1 (https=)
DE (1) DE602006011161D1 (https=)
ES (1) ES2337397T3 (https=)
IL (1) IL188355A0 (https=)
MX (1) MX2007016469A (https=)
NO (1) NO20080304L (https=)
WO (1) WO2007009007A2 (https=)
ZA (1) ZA200800906B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114259564A (zh) * 2021-11-30 2022-04-01 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN115227692A (zh) * 2022-09-05 2022-10-25 中国医学科学院基础医学研究所 Reblastatin在制备治疗慢性惊厥的药物中的用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418147A (pt) 2003-12-23 2007-04-17 Infinity Pharmaceuticals Inc análogos de ansamicinas contendo benzoquinona e seus métodos de uso
EP1863769A4 (en) * 2005-03-11 2009-03-18 Univ Colorado HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
US20100279994A1 (en) * 2005-06-21 2010-11-04 Inifinity Discovery, Inc. Ansamycin Formulations and Methods of Use Thereof
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US20080255080A1 (en) * 2007-04-12 2008-10-16 Wright James L Hydroquinone Ansamycin Formulations
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
ES2616231T3 (es) 2008-08-21 2017-06-12 Immunogenics Llc Formulación para administración oral de proteínas
WO2010045442A1 (en) * 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2012151544A1 (en) 2011-05-05 2012-11-08 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
SG11201608502TA (en) 2014-05-01 2016-11-29 Ionis Pharmaceuticals Inc Compositions and methods for modulating complement factor b expression
US11384104B2 (en) * 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) * 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
FI943207A0 (fi) * 1992-01-06 1994-07-05 Pfizer 4,5-dihydrogeldanamysiinin ja sen hydrokinonin valmistusmenetelmä ja käyttö
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
EP1373215B1 (en) * 2001-03-30 2006-07-26 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Geldanamycin derivatives useful for treating cancer
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1472230B1 (en) * 2002-02-08 2009-06-17 Conforma Therapeutic Corporation Ansamycins having improved pharmacological and biological properties
BRPI0418147A (pt) * 2003-12-23 2007-04-17 Infinity Pharmaceuticals Inc análogos de ansamicinas contendo benzoquinona e seus métodos de uso
EP1863769A4 (en) * 2005-03-11 2009-03-18 Univ Colorado HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114259564A (zh) * 2021-11-30 2022-04-01 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN114259564B (zh) * 2021-11-30 2023-03-14 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN115227692A (zh) * 2022-09-05 2022-10-25 中国医学科学院基础医学研究所 Reblastatin在制备治疗慢性惊厥的药物中的用途

Also Published As

Publication number Publication date
ES2337397T3 (es) 2010-04-23
BRPI0612870A2 (pt) 2010-11-30
KR20080030093A (ko) 2008-04-03
MX2007016469A (es) 2008-04-22
AU2006268196A1 (en) 2007-01-18
IL188355A0 (en) 2008-08-07
ZA200800906B (en) 2009-07-29
EP1904057A2 (en) 2008-04-02
WO2007009007A2 (en) 2007-01-18
US20060019941A1 (en) 2006-01-26
ATE451919T1 (de) 2010-01-15
NO20080304L (no) 2008-02-29
DE602006011161D1 (de) 2010-01-28
EP1904057B1 (en) 2009-12-16
WO2007009007A3 (en) 2007-05-03
JP2009501234A (ja) 2009-01-15
CA2612506A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
CN101267816A (zh) 使用氢醌安沙霉素的治疗方法
JP5313308B2 (ja) 癌治療に使用するベンゾキノン包含アンサマイシン類のアナログ
JP2011225614A5 (https=)
JP6674586B2 (ja) 血液脳関門通過能を有する置換キナゾリン化合物
JP2002541189A (ja) 細胞膜透過性インジゴイドビスインドール誘導体の使用
CN103664734B (zh) 杂环羟肟酸类化合物及其药用组合物和应用
EP3659307A1 (en) Anticancer Drugs and Methods of Making and Using Same
CN101677991A (zh) 氢醌安莎霉素制剂
CN1898212B (zh) 用于治疗癌症的包含苯醌的安沙霉素类似物
AU2020210876A1 (en) Anticancer drugs and methods of making and using same
MXPA06007120A (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080917